References
- Manne BK, Xiang SC, Rondina MT. Platelet secretion in inflammatory and infectious diseases. Platelets. 2017;28(2):155–164. DOI:https://doi.org/10.1080/09537104.2016.1240766
- Rayes J, Bourne JH, Brill A, et al. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2020;4(1):23–35. DOI:https://doi.org/10.1002/rth2.12266
- Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. DOI:https://doi.org/10.1016/S0140-6736(17)31222-9
- Robert L, Labat-Robert J. Platelets, micro-particles and elastase. a review with extrapolation to the mechanism of generation and bio-pathology of platelet fragments. Pathol Oncol Res. 2017;23(2):455–458. DOI:https://doi.org/10.1007/s12253-017-0199-1
- Munoz-Esquerre M, Ferreiro JL, Huertas D, et al. Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis. 2018;13:141–148. DOI:https://doi.org/10.2147/COPD.S152660
- Xu X, Wang H, Wang Z, et al. Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells. Exp Lung Res. 2009;35(9):795–805. DOI:https://doi.org/10.3109/01902140902912519
- Noris P, Melazzini F, Balduini CL. New roles for mean platelet volume measurement in the clinical practice? Platelets. 2016;27(7):607–612. DOI:https://doi.org/10.1080/09537104.2016.1224828
- Vagdatli E, Gounari E, Lazaridou E, et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1):28–32.
- Gasparyan AY, Ayvazyan L, Mukanova U, et al. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med. 2019;39(4):345–357. DOI:https://doi.org/10.3343/alm.2019.39.4.345
- Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute 2013. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. DOI:https://doi.org/10.1186/1471-2288-14-135
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. DOI:https://doi.org/10.1186/1471-2288-5-13
- Bowden J, Tierney JF, Copas AJ, et al. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41. DOI:https://doi.org/10.1186/1471-2288-11-41
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. DOI:https://doi.org/10.1002/sim.1186
- Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;47:15–17.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. DOI:https://doi.org/10.2307/2533446
- Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–1055. DOI:https://doi.org/10.1016/S0895-4356(01)00377-8
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. DOI:https://doi.org/10.1136/bmj.b2700
- Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. DOI:https://doi.org/10.1161/01.cir.0000056767.69054.b3
- Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci. 2008;115(7):225–232. (Lond). DOI:https://doi.org/10.1042/CS20070382
- Biljak VR, Pancirov D, Cepelak I, et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011;22(6):466–470. DOI:https://doi.org/10.3109/09537104.2011.573887
- Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66(9):769–774. DOI:https://doi.org/10.1136/thx.2010.157529
- Steiropoulos P, Papanas N, Nena E, et al. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Angiology. 2013;64(7):535–539. DOI:https://doi.org/10.1177/0003319712461436
- Stoll P, Wuertemberger U, Bratke K, et al. Stage-dependent association of BDNF and TGF-β1 with lung function in stable COPD. Respir Res. 2012;13:116. DOI:https://doi.org/10.1186/1465-9921-13-116
- Ulasli SS, Ozyurek BA, Yilmaz EB, et al. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012;122(6):284–290. DOI:https://doi.org/10.20452/pamw.1284
- Wang R, Cao Z, Li Y, et al. Utility of N-terminal pro B-type natriuretic peptide and mean platelet volume in differentiating congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol. 2013;170(2):e28–e29. DOI:https://doi.org/10.1016/j.ijcard.2013.10.048
- Wang RT, Li JY, Cao ZG, et al. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18(8):1244–1248. DOI:https://doi.org/10.1111/resp.12143
- Günay E, Sarınç Ulaşlı S, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation. 2014;37(2):374–380. DOI:https://doi.org/10.1007/s10753-013-9749-1
- Zhang M, Li Y, Zhang J, et al. Mean platelet volume is elevated in exacerbated and convalescent COPD patients. Clin Chim Acta. 2015;451(Pt B):227–231. DOI:https://doi.org/10.1016/j.cca.2015.10.001
- Agapakis DI, Massa EV, Hantzis I, et al. The role of mean platelet volume in chronic obstructive pulmonary disease exacerbation. Respir Care. 2016;61(1):44–49. DOI:https://doi.org/10.4187/respcare.04132
- Demir M, Acet H, Kaya H, et al. Relationship between metabolic syndrome and epicardial fat tissue thickness in patients with chronic obstructive pulmonary disease. Anatol J Cardiol. 2016;16(6):405–411. DOI:https://doi.org/10.14744/AnatolJCardiol.2015.6566
- Karadeniz G, Aktoğu S, Erer OF, et al. Predictive value of platelet-to-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. Biomark Med. 2016;10(7):701–710. DOI:https://doi.org/10.2217/bmm-2016-0046
- Makhlouf HA, Sadek SH, Nafady AAH. Platelet function in diabetic and nondiabetic patients with chronic obstructive pulmonary disease: a case control study. Clin Respir J. 2018;12(1):48–56. DOI:https://doi.org/10.1111/crj.12477
- Malerba M, Nardin M, Radaeli A, et al. The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients. Expert Rev Hematol. 2017;10(9):821–832. DOI:https://doi.org/10.1080/17474086.2017.1353416
- Aleva FE, Temba G, de Mast Q, et al. Increased platelet-monocyte interaction in stable COPD in the absence of platelet hyper-reactivity. Respiration. 2018;95(1):35–43. DOI:https://doi.org/10.1159/000480457
- Farah R, Ibrahim R, Nassar M, et al. The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD. Panminerva Med. 2017;59(3):203–209.
- Guang Y, Jie Z, Feng D, et al. Surrogate scale for evaluating respiratory function based on complete blood count parameters. J Clin Lab Anal. 2018;32(5):e22385. DOI:https://doi.org/10.1002/jcla.22385
- El-Gazzar AG, Kamel MH, Elbahnasy OKM, et al. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. Expert Rev Respir Med. 2020;14(1):111–116. DOI:https://doi.org/10.1080/17476348.2019.1675517
- Hlapcic I, Somborac-Bacura A, Popovic-Grle S, et al. Platelet indices in stable chronic obstructive pulmonary disease - association with inflammatory markers, comorbidities and therapy. Biochem Med (Zagreb). 2020;30(1):010701.
- Şahin F, Koşar AF, Aslan AF, et al. Serum biomarkers in patients with stable and acute exacerbation of chronic obstructive pulmonary disease: A comparative study. J Med Biochem. 2019;38(4):503–511. DOI:https://doi.org/10.2478/jomb-2018-0050
- Skoczynski S, Krzyzak D, Studnicka A, et al. Chronic obstructive pulmonary disease and platelet count. Adv Exp Med Biol. 2019;1160:19–23.
- Cilingir BM, Sunnetcioglu A. Platelet distribution with is a usable parameter in chronic obstructive pulmonary disease severity. Eastern J Med. 2020;25(1):97–102. DOI:https://doi.org/10.5505/ejm.2020.24572
- Crisafulli E, Cilloniz C, Liapikou A, et al. Systemic inflammatory response and outcomes in community-acquired pneumonia patients categorized according to the smoking habit or presence of chronic obstructive pulmonary disease. JCM. 2020;9(9):2884. DOI:https://doi.org/10.3390/jcm9092884
- Zouaoui Boudjeltia K, Kotsalos C, de Sousa DR, et al. Spherization of red blood cells and platelet margination in COPD patients. Ann N Y Acad Sci. 2021;1485(1):71–82. DOI:https://doi.org/10.1111/nyas.14489
- De Castro J, Hernandez-Hernandez A, Rodriguez MC, et al. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets. 2007;18(1):43–51. DOI:https://doi.org/10.1080/09537100600800776
- Eriksson O, Mohlin C, Nilsson B, et al. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol. 2019;10:1590.
- Melki I, Tessandier N, Zufferey A, et al. Platelet microvesicles in health and disease. Platelets. 2017;28(3):214–221. DOI:https://doi.org/10.1080/09537104.2016.1265924
- Sprague DL, Sowa JM, Elzey BD, et al. The role of platelet CD154 in the modulation in adaptive immunity. Immunol Res. 2007;39(1–3):185–193. DOI:https://doi.org/10.1007/s12026-007-0074-3
- Lefrancais E, Looney MR. Platelet Biogenesis in the Lung Circulation. Physiology (Bethesda). 2019;34(6):392–401. DOI:https://doi.org/10.1152/physiol.00017.2019
- Mallah H, Ball S, Sekhon J, et al. Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. Respir Med. 2020;171:106098. DOI:https://doi.org/10.1016/j.rmed.2020.106098
- Lonky SA, Wohl H. Stimulation of human leukocyte elastase by platelet factor 4. Physiologic, morphologic, and biochemical effects on hamster lungs in vitro. J Clin Invest. 1981;67(3):817–826. DOI:https://doi.org/10.1172/JCI110099
- Wu K, Tang H, Lin R, et al. Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension. Pulm Circ. 2020;10(3):2045894020948470. DOI:https://doi.org/10.1177/2045894020948470
- Chaurasia SN, Kushwaha G, Kulkarni PP, et al. Platelet HIF-2α promotes thrombogenicity through PAI-1 synthesis and extracellular vesicle release. Haematologica. 2019;104(12):2482–2492. DOI:https://doi.org/10.3324/haematol.2019.217463
- Wang H, Yang T, Li D, et al. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. COPD. 2016;11:2369–2376. DOI:https://doi.org/10.2147/COPD.S107409
- Tian C, Song W, Tian X, et al. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: a meta-analysis. Eur J Clin Invest. 2018;48(5):e12917. DOI:https://doi.org/10.1111/eci.12917
- Erre GL, Buscetta G, Mangoni AA, et al. Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: a cross-sectional study. Med (Baltimore). 2020;99(44):e22557. DOI:https://doi.org/10.1097/MD.0000000000022557
- Paliogiannis P, Satta R, Deligia G, et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med. 2019;19(1):37–45. DOI:https://doi.org/10.1007/s10238-018-0538-x
- Ma Y, Zong D, Zhan Z, et al. Feasibility of mean platelet volume as a biomarker for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Int Med Res. 2019;47(12):5937–5949. DOI:https://doi.org/10.1177/0300060519887886
- Fawzy A, Putcha N, Paulin LM, SPIROMICS and COPDGene Investigators, et al. Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. Respir Res. 2018;19(1):20. DOI:https://doi.org/10.1186/s12931-018-0717-z
- Korniluk A, Koper-Lenkiewicz OM, Kaminska J, et al. Mean Platelet Volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019;2019:9213074. DOI:https://doi.org/10.1155/2019/9213074
- Pujani M, Chauhan V, Singh K, et al. The effect and correlation of smoking with platelet indices, neutrophil lymphocyte ratio and platelet lymphocyte ratio. Hematol Transfus Cell Ther. 2020. DOI:https://doi.org/10.1016/j.htct.2020.07.006.
- Corriere T, Di Marca S, Cataudella E, et al. Neutrophil-to-Lymphocyte Ratio is a strong predictor of atherosclerotic carotid plaques in older adults. Nutr Metab Cardiovasc Dis. 2018;28(1):23–27. DOI:https://doi.org/10.1016/j.numecd.2017.10.022
- Reddy SK, Shetty R, Marupuru S, et al. Significance of platelet volume indices in STEMI Patients: a case-control study. J Clin Diagn Res. 2017;11(4):LC05–LC07.
- Pavasini R, Biscaglia S, d'Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD Patients: a systematic review and meta-analysis. COPD. 2016;13(4):509–514. DOI:https://doi.org/10.3109/15412555.2015.1099620